SplitJul 30, 2026, 12:11 PM
Lexaria Bioscience Announces 1-for-15 Reverse Stock Split
AI Summary
Lexaria Bioscience Corp. announced a 1-for-15 reverse stock split of its common stock, effective August 3, 2026. The company stated the primary goal is to regain compliance with the NASDAQ Capital Market's minimum $1.00 bid price requirement and to stabilize stock conditions to attract new business development partners. Post-split, authorized shares will decrease to 14,666,667 and outstanding shares to approximately 1,652,518, with fractional shares rounded up.
Key Highlights
- 1-for-15 reverse stock split of common stock authorized.
- Effective date for trading on a split-adjusted basis is August 3, 2026.
- Primary reason is to regain compliance with NASDAQ's minimum $1.00 bid price rule.
- Secondary reason is to stabilize stock conditions and attract business partners.
- Authorized shares will be reduced from 220,000,000 to 14,666,667.
- Outstanding shares will be reduced from 24,787,446 to approximately 1,652,518.
- Fractional shares will be rounded up to the nearest whole share.
- Shares will trade under a new CUSIP number, 52886N604.
Price Impact
More from LEXX